Background: Empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor is used as a monotherapy or in combination for lowering the elevated blood glucose level in patients with type 2 diabetes mellitus (T2DM). It is often associated with certain adverse reactions (urinary tract infection (UTI), diabetes ketoacidosis (DKA), and genital infections). Thus, the Saudi Food and Drug Administration requested a post-authorisation safety study to monitor the safety of empagliflozin during the defined observation period. Methodology: The local, comparator, non-interventional, regulatory post-marketing study using “new user” design was conducted in patients with T2DM, treated with empagliflozin (10 or 25 mg) and dipeptidyl peptidase-4 (DPP-4) inhibitors (NCT03764631). Study was conducted from 2018 to 2020, wherein each patient was followed up for 12 months after the index period. Incidence and occurrence of DKA, severe UTIs, volume depletion and dehydration were observed along with metformin, insulin and treatment complexity status and adverse events in the index and Ramadan period. All data collected were analysed using descriptive statistics. Results: Among the 1502 patients enrolled (empagliflozin [n = 751] and DPP-4 inhibitors [n = 751]), 0.1% patients (n = 1) in each group and <1% patients (n = 13) (0.8% [n = 6]: empagliflozin group; 0.9% [n = 7]: DPP-4 inhibitor group) reported the incidence of DKA and volume depletion, respectively. No severe UTIs or dehydration was evident in either group in the index period. No patients reported T2DM-associated complications during the Ramadan period. Metformin, insulin, and treatment complexity status were also evaluated during the study. Overall, 8.1% of patients (n = 121) reported adverse events in the index period while only 0.3% of patients (n = 4) reported adverse events during the Ramadan period. Comparable decline in mean glycated haemoglobin, and no major change in vital signs, along with 81.3% of patients (n = 1221) confirming concomitant medications were noted. Conclusion: Empagliflozin was well tolerated over a period of 12 months, with no safety concerns and a favourable benefit/risk ratio.
References
[1]
Hassoun, A., Dhanwal, D., Nafach, J., Ajaz, Y., Khan, A., Nakhi, A., et al. (2022) Real-World Assessment of Efficacy and Safety Parameters for Dapagliflozin in Management of Type 2 Diabetes Mellitus: REWARD Study. Dubai Diabetes and Endocrinology Journal, 28, 25-34. https://doi.org/10.1159/000519871
[2]
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K.B., et al. (2020) Pathophysiology of Type 2 Diabetes Mellitus. International Journal of Molecular Sciences, 21, Article No. 6275. https://doi.org/10.3390/ijms21176275
[3]
IDF MENA Members. International Diabetes Federation. https://idf.org/our-network/regions-members/middle-east-and-north-africa/members/46-saudi-arabia.html
[4]
Gelhorn, H.L., Boye, K.S., Shalhoub, H., Matza, L.S., Jordan, J.B., et al. (2020) Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia. Patient Preference and Adherence, 14, 2231-2242. https://doi.org/10.2147/PPA.S265126
[5]
Abdulaziz Al Dawish, M., Alwin Robert, A., Braham, R., Abdallah Al Hayek, A., Saeed, A., Ahmed, R., et al. (2016) Diabetes Mellitus in Saudi Arabia: A Review of the Recent Literature. Current Diabetes Reviews, 12, 359-368. https://doi.org/10.2174/1573399811666150724095130
[6]
World Health Organization (2016) Saudi Arabia Diabetes Data. World Health Organization, Geneva.
[7]
Meo, S.A. (2016) Prevalence and Future Prediction of Type 2 Diabetes Mellitus in the Kingdom of Saudi Arabia: A Systematic Review of Published Studies. Journal of Pakistan Medical Association, 66, 722-725.
[8]
Tanveer, M.S., Tanveer, M.H. and Javed, M. (2021) Type 2 Diabetes Mellitus in Saudi Arabia: A Review of the Current Situation. Journal of Diabetology, 12, 270-274. https://doi.org/10.4103/JOD.JOD_92_20
[9]
Gökçay Canpolat, A. and Şahin, M. (2020) Glucose Lowering Treatment Modalities of Type 2 Diabetes Mellitus. In: Islam, M.S.m Ed., Diabetes: From Research to Clinical Practice. Advances in Experimental Medicine and Biology, Vol. 1307, Springer, Cham, 7-27. https://doi.org/10.1007/5584_2020_516
[10]
Al-Arouj, M., Bouguerra, R., Buse, J., Hafez, S., Hassanein, M., Ibrahim, M.A., et al. (2005) Recommendations for Management of Diabetes during Ramadan. Diabetes Care, 28, 2305-2311. https://doi.org/10.2337/diacare.28.9.2305
[11]
Jaleel, M.A., Raza, S.A., Fathima, F.N. and Jaleel, B.N.F. (2011) Ramadan and Diabetes: As-Saum (The Fasting). Indian Journal of Endocrinology and Metabolism, 15, 268-273. https://doi.org/10.4103/2230-8210.85578
[12]
International Diabetes Federation (2021) IDF Diabetes Atlas. 10th Edition. https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf
[13]
Fattah, H. and Vallon, V. (2018) The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus. Drugs, 78, 717-726. https://doi.org/10.1007/s40265-018-0901-y
[14]
Alguwaihes, A.M. (2021) Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post Authorization Safety Study. Diabetes Therapy, 12, 1979-1992. https://doi.org/10.1007/s13300-021-01092-0
[15]
Baron, K.T., Macha, S., Broedl, U.C., Nock, V., Retlich, S. and Riggs, M. (2016) Population Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes. Diabetes Therapy, 7, 455-471. https://doi.org/10.1007/s13300-016-0174-y
[16]
Utsunomiya, K., Koshida, R., Kakiuchi, S., Senda, M., Fujii, S., Kurihara, Y., et al. (2021) Safety and Effectiveness of Tofogliflozin in Japanese Patients with Type 2 Diabetes Mellitus Treated in Real-World Clinical Practice: Results of a 36-Month Post-Marketing Surveillance Study (J-STEP/LT). Journal of Diabetes Investigation, 12, 184-199. https://doi.org/10.1111/jdi.13333
[17]
Kadowaki, T., Haneda, M., Inagaki, N., Terauchi, Y., Taniguchi, A., Koiwai, K., et al. (2015) Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study. Advances in Therapy, 32, 306-318. https://doi.org/10.1007/s12325-015-0198-0
[18]
Shi, F.-H, Li, H., Shen, L., Fu, J.-J., Ma, J., Gu, Z.-C., et al. (2021) High-Dose Sodium-Glucose Co-Transporter-2 Inhibitors Are Superior in Type 2 Diabetes: A Meta-Analysis of Randomized Clinical Trials. Diabetes, Obesity and Metabolism, 23, 2125-2136. https://doi.org/10.1111/dom.14452
[19]
Kovacs, C.S., Seshiah, V., Swallow, R., Jones, R., Rattunde, H., Woerle, H.J., et al. (2014) Empagliflozin Improves Glycaemic and Weight Control as Add-On Therapy to Pioglitazone or Pioglitazone plus Metformin in Patients with Type 2 Diabetes: A 24-Week, Randomized, Placebo-Controlled Trial. Diabetes, Obesity and Metabolism, 16, 147-158. https://doi.org/10.1111/dom.12188
[20]
Merker, L., Häring, H.-U., Christiansen, A.V., Roux, F., Salsali, A., Kim, G., et al. (2015) Empagliflozin as Add-On to Metformin in People with Type 2 Diabetes. Diabetic Medicine, 32, 1555-1567. https://doi.org/10.1111/dme.12814
[21]
Häring, H.U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Broedl, U.C., et al. (2014) Empagliflozin as Add-On to Metformin in Patients with Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care, 37, 1650-1659. https://doi.org/10.2337/dc13-2105
[22]
Hassanein, M., Al Sifri, S., Shaikh, S., Raza, S.A., Akram, J., Rudijanto, A., et al. (2021) Descriptive Regional Subanalysis of a Real-World Study in Patients with Type 2 Diabetes Treated with Gliclazide MR during Fasting: DIA-RAMADAN. Diabetes Therapy, 12, 1703-1719. https://doi.org/10.1007/s13300-021-01067-1
[23]
Sanyal, D., Majumder, A., Ghosh, S. and Pandit, K. (2021) Real World Study of Short Term Efficacy, Safety, and Tolerability of Canagliflozin 100 mg Initiation in Type 2 Diabetes Mellitus Patients during Hot Humid Indian Summer. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15, 385-389. https://doi.org/10.1016/j.dsx.2021.01.011
[24]
Terauchi, Y., Fujiwara, H., Kurihara, Y., Suganami, H., Tamura, M., Senda, M., et al. (2019) Long-Term Safety and Efficacy of the Sodium-Glucose Cotransporter 2 Inhibitor, Tofogliflozin, Added on Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes Mellitus: A 52-Week Open-Label, Multicenter, Post-Marketing Clinical Study. Journal of Diabetes Investigation, 10, 1518-1526. https://doi.org/10.1111/jdi.13066
[25]
Lega, I.C., Bronskill, S.E., Campitelli, M.A., Guan, J., Stall, N.M., Lam, K., et al. (2019) Sodium Glucose Cotransporter 2 Inhibitors and Risk of Genital Mycotic and Urinary Tract Infection: A Population-Based Study of Older Women and Men with Diabetes. Diabetes, Obesity and Metabolism, 21, 2394-2404. https://doi.org/10.1111/dom.13820
[26]
Jabbour, S., Seufert, J., Scheen, A., Bailey, C.J., Karup, C. and Langkilde, A.M. (2018) Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Safety Data from Phase IIb/III Clinical Trials. Diabetes, Obesity and Metabolism, 20, 620-628. https://doi.org/10.1111/dom.13124
[27]
Zaccardi, F., Webb, D.R., Htike, Z.Z., Youssef, D., Khunti, K. and Davies, M.J. (2016) Efficacy and Safety of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 2 Diabetes Mellitus: Systematic Review and Network Meta-Analysis. Diabetes, Obesity and Metabolism, 18, 783-94. https://doi.org/10.1111/dom.12670
[28]
Kohler, S., Zeller, C., Iliev, H. and Kaspers, S. (2017) Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials. Advances in Therapy, 34, 1707-1726. https://doi.org/10.1007/s12325-017-0573-0
[29]
Roden, M., Weng, J., Eilbracht, J., Delafont, B., Kim, G., Woerle, H.J., et al. (2013) Empagliflozin Monotherapy with Sitagliptin as an Active Comparator in Patients with Type 2 Diabetes: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Diabetes and Endocrinology, 1, 208-219. https://doi.org/10.1016/S2213-8587(13)70084-6
[30]
Kinduryte Schorling, O., Clark, D., Zwiener, I., Kaspers, S., Lee, J. and Iliev, H. (2020) Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus. Advances in Therapy, 37, 3463-3484. https://doi.org/10.1007/s12325-020-01329-7
[31]
Wu, X.-Y., She, D.-M., Wang, F., Guo, G., Li, R., Fang, P., et al. (2020) Clinical Profiles, Outcomes and Risk Factors among Type 2 Diabetic Inpatients with Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State: A Hospital-Based Analysis over a 6-Year Period. BMC Endocrine Disorders, 20, Article No. 182. https://doi.org/10.1186/s12902-020-00659-5
[32]
Sharma, P.V., Jobanputra, Y.B., Lewin, K., Bagatell, S. and Lichtstein, D.M. (2018) Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors—A Case Series. Reviews on Recent Clinical Trials, 13, 156-160. https://doi.org/10.2174/1574887113666180314101436
[33]
Eledrisi, M.S. and Elzouki, A.-N. (2020) Management of Diabetic Ketoacidosis in Adults: A Narrative Review. Saudi Journal of Medicine and Medical Sciences, 8, 165-173. https://doi.org/10.4103/sjmms.sjmms_478_19
[34]
Wang, L., Voss, E.A., Weaver, J., Hester, L., Yuan, Z., DeFalco, F., et al. (2019) Diabetic Ketoacidosis in Patients with Type 2 Diabetes Treated with Sodium Glucose Co-Transporter 2 Inhibitors versus Other Antihyperglycemic Agents: An Observational Study of Four US Administrative Claims Databases. Pharmacoepidemiology and Drug Safety, 28, 1620-1628. https://doi.org/10.1002/pds.4887
[35]
Aamir, A.H., Raja, U.Y., Asghar, A., Mahar, S.A., Ghaffar, T., Ahmed, I., et al. (2021) Asymptomatic Urinary Tract Infections and Associated Risk Factors in Pakistani Muslim Type 2 Diabetic Patients. BMC Infectious Diseases, 21, Article No. 388. https://doi.org/10.1186/s12879-021-06106-7
[36]
He, K., Hu, Y., Shi, J.C., Zhu, Y.Q. and Mao, X.M. (2018) Prevalence, Risk Factors and Microorganisms of Urinary Tract Infections in Patients with Type 2 Diabetes Mellitus: A Retrospective Study in China. Therapeutics and Clinical Risk Management, 14, 403-408. https://doi.org/10.2147/TCRM.S147078
[37]
Hirji, I., Guo, Z., Andersson, S.W., Hammar, N. and Gomez-Caminero, A. (2012) Incidence of Urinary Tract Infection among Patients with Type 2 Diabetes in the UK General Practice Research Database (GPRD). Journal of Diabetes and Its Complications, 26, 513-516. https://doi.org/10.1016/j.jdiacomp.2012.06.008
[38]
Salari, N., Karami, M.M., Bokaee, S., Chaleshgar, M., Shohaimi, S., Akbari, H., et al. (2022) The Prevalence of Urinary Tract Infections in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis. European Journal of Medical Research, 27, Article No. 20. https://doi.org/10.1186/s40001-022-00644-9
[39]
Higashikawa, T., Ito, T., Mizuno, T., Ishigami, K., Kohori, M., Mae, K., et al. (2018) The Effects of 12-Month Administration of Tofogliflozin on Electrolytes and Dehydration in Mainly Elderly Japanese Patients with Type 2 Diabetes Mellitus. Journal of International Medical Research, 46, 5117-5126. https://doi.org/10.1177/0300060518790870
[40]
Patel, S.M., Hickman, M.A., Frederich, R., Lauring, B., Terra, S., Johnson, S.L., et al. (2018) Evaluation of Osmotic Diuresis and Volume Depletion Events in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin. Diabetes, 67, Article No. 1169-P. https://doi.org/10.2337/db18-1169-P
[41]
Bener, A. and Yousafzai, M.T. (2014) Effect of Ramadan Fasting on Diabetes Mellitus: A Population-Based Study in Qatar. The Journal of the Egyptian Public Health Association, 89, 47-52. https://doi.org/10.1097/01.EPX.0000451852.92252.9b
[42]
Gad, H., Al-Nassr, N., Mohammed, I., Khan, A., MacDonald, R., Mussleman, P., et al. (2011) Effect of Ramadan Fasting in Patients with Type 2 Diabetes Mellitus Treated with Sodium-Glucose Cotransporter 2 Inhibitors: A Systematic Review and Meta-Analysis. Journal of Diabetes Investigation, 13, 822-829. https://doi.org/10.1111/jdi.13741
[43]
Hassoun, A.A., Al-Arouj, M. and Ibrahim, M. (2017) The Effect of Vildagliptin Relative to Sulfonylurea as Dual Therapy with Metformin (or as Monotherapy) in Muslim Patients with Type 2 Diabetes Fasting during Ramadan in the Middle East: The VIRTUE Study. Current Medical Research and Opinion, 33, 161-167. https://doi.org/10.1080/03007995.2016.1243093
